WEBINAR:
AI Meets Chemistry
Discover Standigm's use of SYNTHIATM tools to accelerate AI-driven drug discovery and enhance molecule development.
Standigm showcases its innovative use of SYNTHIATM webapp, SYNTHIATM SAS API, and SYNTHIATM full retro API to revolutionize drug discovery through AI. Discover how these tools are bridging critical gaps in medical research by accelerating the development of therapeutic solutions. Ideal for professionals in chemistry, biology, and AI, this session will serve as a comprehensive tutorial, enhancing your understanding of AI's transformative role in pharmaceuticals. Don’t miss this opportunity to be at the forefront of AI-driven drug discovery advancements!
Key Learning Objectives:
- How Standigm integrates SYNTHIATM’s tools to expedite the drug discovery process, enhancing efficiency and output.
- The specific functionalities and advantages of SYNTHIATM webapp, SYNTHIATM SAS API, and full retro API in real-world pharmaceutical applications.
- Strategies for leveraging AI in drug discovery to identify and assess novel drug targets and design effective molecular modulators.
Speaker
Dr. Ewa Gajewska holds a position of a Head of Product Management in Merck, Darmstadt, Germany where she leads the development of SYNTHIA™ Retrosynthesis Software. She graduated in biotechnology and chemistry from the Gdansk University of Technology and was a recipient of the Outstanding Achievements Award from Poland’s Minister of Science and Higher Education. In 2020 she received her PhD from the Institute of Organic Chemistry at the Polish Academy of Sciences. Her doctoral work was devoted to development of the SYNTHIA™ Retrosynthesis Software for computer-assisted synthetic planning. Her passion for tackling complex scientific challenges within commercial settings and the unique blend of her interdisciplinary skills drive the realization of innovative features of SYNTHIA™ Retrosynthesis Software.
Dr. You Young Song is a Principal AI Scientist at Standigm, specializing in generative and synthesis AI for drug discovery. She holds a degree in computer science and technology, and mathematics from POSTECH in South Korea and earned her PhD from the Graduate Institute of Ferrous & Energy Materials Technology at POSTECH. Throughout her doctoral studies and before joining Standigm, she focused on computer-based simulations to develop novel enhanced materials, which ultimately led her to dedicate herself to AI-based drug discovery.
Standigm
Established as a pioneer in AI-driven drug discovery, Standigm utilizes cutting-edge artificial intelligence to streamline the development of pharmaceuticals. With a robust AI platform that includes biology and chemistry components, Standigm accelerates the discovery of novel drug targets and molecular designs, aiming to revolutionize patient care globally.